Vitarka Therapeutics

Curing the Untreated

Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets in Oncology, Neuroscience Pain and Neurodegenerative diseases.                          


Our therapeutic cargoes are siRNA, ASO and peptides.


EndoPore delivers up to 80% therapeutic cargo into the cytosol, compared to less than 1% delivered by Lipid NanoParticles.


We are maturing a pipeline of first-in-class therapeutics, in collaboration with Pharma.


Up to 80% CARGO DELIVERED INTO THE CYTOSOL

TRANSFORMATIVE

 

EndoPore is flexible and modular to carry a variety of cargoes into several cell types, including tumour cells, motor neurons and sensory neurons

 VALIDATED IN DISEASE MODELS

 

EndoPore had been tested in cell and animal-based disease-relevant models. The cell-binding domain has been tested in human clinical trials proof-of-concept

SPECIFICITY

 

EndoPore specifically targets and binds to cell surface recpetors. It uses these to enter the cells and then releases therapeutic cargo into the cytosol by forming a translocation channel in the endosomal membrane.

SCALABLE

 

EndoPore has been produced in large scale, with processes ready to GMP-grade transger. Several grams of EndoPore can be yielded from 1L culture

About Us


We are an experienced leadership team with proven track record in Ppharma drug development including project management, target discovery, lead identification, optimization and clinical development.


We work with a strong strategic network alliance of collaborators, experts, partners, associates and counsellors.